---
title: "Semaglutide"
canonical_url: https://peptidelibrary.app/library/semaglutide
description: "FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program)."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Semaglutide

Semaglutide (also called Ozempic or Wegovy) is an FDA-approved GLP-1 receptor agonist. GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Fatty-acid acylation extends half-life to about 1 week. FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).

FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program).

Also known as: Ozempic, Wegovy, Rybelsus, NN9535.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: FDA-approved GLP-1 receptor agonist
- Mechanism class: GLP-1 Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Fatty-acid acylation extends half-life to about 1 week.

Targets: GLP-1 receptor.

Origin: Acylated human GLP-1 analog.

## Properties

- Molecular formula: C187H291N45O59
- Molecular weight: 4,113.58 g/mol
- CAS number: 910463-68-2
- Half-life: Approximately 1 week
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2021

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with obesity, or overweight with a weight-related condition. Chronic weight management [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
2. WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with established cardiovascular disease and obesity or overweight. Major adverse cardiovascular events [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3. OZEMPIC (semaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with type 2 diabetes mellitus. Glycaemic control; cardiovascular and renal outcomes [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. 2021. Controlled human trial. Population: Adults with BMI ≥30, or ≥27 with a weight-related condition, without diabetes. Percentage change in body weight [Source](https://pubmed.ncbi.nlm.nih.gov/33567185/)

## Safety

Side effects: Nausea; Vomiting; Diarrhea; Constipation; Abdominal pain; Decreased appetite; Gastroesophageal reflux; Pancreatitis (rare); Diabetic retinopathy complications (rare).

Risks: Unregulated products may be mislabeled/contaminated; injection risks; unknown long‑term safety..

Contraindications: Personal/family history of MTC or MEN2; Prior serious hypersensitivity.

Human safety basis: FDA prescribing information

## Regulatory status

Semaglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Semaglutide?

FDA-approved long-acting GLP-1 agonist for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy). Weekly injection or daily oral tablet. Not WADA-prohibited (monitoring program). GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Fatty-acid acylation extends half-life to about 1 week.

### What are the side effects of Semaglutide?

Side effects recorded for Semaglutide from its prescribing information include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, gastroesophageal reflux, pancreatitis (rare) and diabetic retinopathy complications (rare). Cautions recorded on this profile: personal/family history of MTC or MEN2 and prior serious hypersensitivity. Research-grade vials sold online are not the licensed product. This is reference information, not medical advice.

### How does Semaglutide work?

GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways. Fatty-acid acylation extends half-life to about 1 week.

### Is Semaglutide FDA approved?

Yes. Semaglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Semaglutide?

Reported half-life for Semaglutide is ~7 days. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Semaglutide banned in sport?

Semaglutide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Semaglutide?

Compounds most often compared with Semaglutide include Tirzepatide, Retatrutide, Liraglutide and Exenatide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA Ozempic label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf)
- [Clinical Pharmacokinetics of Semaglutide: A Systematic Review — Drug Des Devel Ther, 2024](https://pubmed.ncbi.nlm.nih.gov/38952487/)
- [Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials — Diabetologia, 2024](https://pubmed.ncbi.nlm.nih.gov/38613667/)
- [Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis — Endocrinol Diabetes Nutr (Engl Ed), 2024](https://pubmed.ncbi.nlm.nih.gov/38555109/)
- [Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review — Int J Mol Sci, 2024](https://pubmed.ncbi.nlm.nih.gov/38673931/)
- [Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis — J ASEAN Fed Endocr Soc, 2022](https://pubmed.ncbi.nlm.nih.gov/36578889/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
